HONG KONG, July 11, 2013 /PRNewswire/ --
Syneron Medical, a Global Leader in devices for aesthetic medicine to present latest technologies to meet growing demands for enhanced body beauty at 9th Asian Dermatological Congress in Hong Kong
Syneron Medical Ltd. (NASDAQ: ELOS), a leading global aesthetic device company, announced today, during the 9th Asian Dermatological Congress, the results of a recent survey on body shaping among Asian populations as well as the latest technologies allowing for best in class, non-invasive, energy based solutions for body shaping indications.
(Logo: http://photos.prnewswire.com/prnh/20120528/535447 )
61% of Hong Kong women dissatisfied with their current body shape
A recent survey sponsored by Syneron and conducted by The Nielsen Company, in April and May of 2013, showed that while looking good is extremely important to Asian women (49% in Hong Kong alone), a vast majority of Asian women in Hong Kong, Taiwan and Australia are concerned by their body shape. Up to 75% (46% in Australia, 61% in Hong Kong and 75% in Taiwan) of the 500 women surveyed in each country and region, aged 25 to 49, said that they were dissatisfied with their current body shape. Women expressing these dissatisfactions were mainly single in Hong Kong and Taiwan, while in Australia, the highest number of concerned women were married. According to the survey the most common body shape concerns include love handles or bra fat and tummy bulge. Among them, love handles or bra fat and tummy bulge are at the top of the list in all three countries and regions with over 49% of the respondents claiming these physical signs to be key concerns.
Syneron committed to supporting body contouring market dynamics
"Customer satisfaction, patient safety and minimal downtime represent our absolute priorities", confirmed Shimon Eckhouse, PhD, co-founder and Chief Executive Officer of Syneron Medical Ltd. "We are passionate about our science and the results we can achieve with our VelaShape, non-invasive circumferential reduction and cellulite treatment technology and with our UltraShape non-invasive fat destruction technology. These technologies and our continuous investment in their improvement build our customer trust and the confidence in our brands." A 2012 Global Aesthetic Market research report from Medical Insight, Inc. confirms that body shaping and skin tightening will continue to drive the multi-billion dollar growth of the aesthetic market. Syneron has allocated specific resources to this particular market segment with targeted research & development activities and new upgrades for its two main body shaping platforms, VelaShape™ and UltraShape®.
In his presentation of the unique features of these two different technologies, Dr. Robert Weiss, Vice President of the American Society for Lasers in Medicine and Surgery, mentioned "we are quite pleased to see how these services are providing women with visible results and increased self-confidence. Doctors have been able to reach a significant reduction of centimeters in circumference with VelaShape and the pulsed focused ultrasound technology of the UltraShape system is allowing patients to get rid of localized fat deposits with no swelling, bruising or downtime. "
Two unique, safe and effective technologies
UltraShape is the only non-invasive, painless non-thermal and non-surgical procedure that instantly and selectively destroys fat cells alone, allowing their contents to then be processed by the body's natural physiological and metabolic pathways.
VelaShape is a medical device based on the combination of four technologies including the revolutionary elos combination of bipolar radiofrequency (RF) and infrared light energy plus vacuum and mechanical massage. It is the first FDA cleared device for treatment of cellulite and circumferential reduction of the thighs.
About Syneron Medical Ltd.
Syneron Medical Ltd. (NASDAQ: ELOS) is the leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under two distinct brands, Syneron and Candela. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and manufacturing operations in the US. The Company markets, services and supports its products in 90 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, Mainland China, Japan, and Hong Kong and distributors worldwide.
Safe Harbor for Forward-looking Statements
Any statements contained in this document regarding future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Further, any statements that are not statements of historical fact (including statements containing "believes," "anticipates," "plans," "expects," "may," "will," "would," "intends," "estimates" and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, such as the company's ability to effectively market the new enhancements, as well as the risks set forth in Syneron Medical Ltd.'s most recent Annual Report on Form 20-F, and the other factors described in the filings that Syneron Medical Ltd. makes with the SEC from time to time. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, Syneron Medical Ltd.'s actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements.
In addition, the statements in this document reflect the expectations and beliefs of Syneron Medical Ltd. as of the date of this document. Syneron Medical Ltd. anticipates that subsequent events and developments will cause its expectations and beliefs to change. However, while Syneron Medical Ltd. may elect to update these forward-looking statements publicly in the future, it specifically disclaims any obligation to do so. The forward-looking statements of Syneron Medical Ltd. do not reflect the potential impact of any future dispositions or strategic transactions that may be undertaken. These forward-looking statements should not be relied upon as representing Syneron Medical Ltd.'s views as of any date after the date of this document.
Contact Details:
Syneron Public Relations pr@syneron.com
Syneron Investors Relations ir@syneron.com
Hugo Goldman, Chief Financial Officer Email: hugo.goldman@syneron.com
Zack Kubow, The Ruth Group +1-646-536-7020 Email: zkubow@theruthgroup.com
